Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Gracell Biotechnologies I...

    NASDAQ: GRCL · Real-Time Price · USD
    10.25
    0.01 (0.05%)
    At close: Feb 21, 2024, 9:00 PM

    Gracell Biotechnologies Statistics

    Share Statistics

    Gracell Biotechnologies has 96.57M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 96.57M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 145,000

    FTD / Avg. Volume

    n/a
    		 9.9%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -2.81 and the forward PE ratio is null. Gracell Biotechnologies's PEG ratio is 0.14.

    PE Ratio

    n/a
    		 -2.81

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 1.24

    P/FCF Ratio

    n/a
    		 -3.21

    PEG Ratio

    n/a
    		 0.14
    Financial Ratio History

    Enterprise Valuation

    Gracell Biotechnologies has an Enterprise Value (EV) of 433.44M.

    EV / Sales

    n/a
    		 0

    EV / EBITDA

    n/a
    		 -0.73

    EV / EBIT

    n/a
    		 -0.9

    EV / FCF

    n/a
    		 -0.82

    Financial Position

    The company has a current ratio of 6.78, with a Debt / Equity ratio of 0.13.

    Current Ratio

    n/a
    		 6.78

    Quick Ratio

    n/a
    		 6.9

    Debt / Equity

    n/a
    		 0.13

    Debt / EBITDA

    n/a
    		 -0.31

    Debt / FCF

    n/a
    		 -0.05

    Interest Coverage

    n/a
    		 -92.72

    Financial Efficiency

    Return on Equity is -44.16% and Return on Invested Capital is -40.08%.

    Return on Equity

    n/a
    		 -44.16%

    Return on Assets

    n/a
    		 -36.68%

    Return on Invested Capital

    n/a
    		 -40.08%

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,934,742.04

    Employee Count

    n/a
    		 314

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 22K

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is -0.34, so Gracell Biotechnologies's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.34

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 9.23

    200-Day Moving Average

    n/a
    		 5.05

    Relative Strength Index (RSI)

    n/a
    		 68.18

    Average Volume (20 Days)

    n/a
    		 1,464,475

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -624.66M

    Net Income

    n/a
    		 -607.51M

    EBITDA

    n/a
    		 -592.58M

    EBIT

    n/a
    		 -600.75M

    Earnings Per Share (EPS)

    n/a
    		 -5.65
    Full Income Statement

    Balance Sheet

    The company has 1.45B in cash and 182.98M in debt, giving a net cash position of 1.27B.

    Cash & Cash Equivalents

    n/a
    		 1.45B

    Total Debt

    n/a
    		 182.98M

    Net Cash

    n/a
    		 1.27B

    Retained Earnings

    n/a
    		 -1.63B

    Total Assets

    n/a
    		 1.89B

    Working Capital

    n/a
    		 1.54B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -3.31B and capital expenditures -331.55M, giving a free cash flow of -3.64B.

    Operating Cash Flow

    n/a
    		 -3.31B

    Capital Expenditures

    n/a
    		 -331.55M

    Free Cash Flow

    n/a
    		 -3.64B

    FCF Per Share

    n/a
    		 -4.94
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    GRCL does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -35.63%

    FCF Yield

    n/a
    		 -31.14%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for GRCL.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 0.7

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist